Subbarao Kanta, McAuliffe Josephine, Vogel Leatrice, Fahle Gary, Fischer Steven, Tatti Kathleen, Packard Michelle, Shieh Wun-Ju, Zaki Sherif, Murphy Brian
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA.
J Virol. 2004 Apr;78(7):3572-7. doi: 10.1128/jvi.78.7.3572-3577.2004.
Following intranasal administration, the severe acute respiratory syndrome (SARS) coronavirus replicated to high titers in the respiratory tracts of BALB/c mice. Peak replication was seen in the absence of disease on day 1 or 2, depending on the dose administered, and the virus was cleared within a week. Viral antigen and nucleic acid were detected in bronchiolar epithelial cells during peak viral replication. Mice developed a neutralizing antibody response and were protected from reinfection 28 days following primary infection. Passive transfer of immune serum to naïve mice prevented virus replication in the lower respiratory tract following intranasal challenge. Thus, antibodies, acting alone, can prevent replication of the SARS coronavirus in the lung, a promising observation for the development of vaccines, immunotherapy, and immunoprophylaxis regimens.
经鼻内给药后,严重急性呼吸综合征(SARS)冠状病毒在BALB/c小鼠的呼吸道中大量复制。根据给药剂量的不同,在第1天或第2天病毒复制达到峰值,此时并无疾病症状出现,且病毒在一周内被清除。在病毒复制高峰期,在细支气管上皮细胞中检测到病毒抗原和核酸。小鼠产生了中和抗体反应,并在初次感染28天后受到保护,免受再次感染。将免疫血清被动转移至未感染的小鼠,可防止鼻内攻击后病毒在下呼吸道复制。因此,单独发挥作用的抗体可预防SARS冠状病毒在肺部的复制,这对于疫苗、免疫疗法和免疫预防方案的开发而言是一个很有前景的观察结果。